Search Results

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, announced that it will report first quarter 2024 financial results on May 9, 2024, after the U.S. financial markets close.

ADMA Biologics, Inc. announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 6, 2024, at 11:35 a.m. ET.

ADMA Biologics, Inc. announced the United States Food and Drug Administration’s approval for its supplemental Biologics License Applications for both ASCENIV and BIVIGAM to extend the approved 4-week room temperature storage conditions during the first 24 months of shelf life, to allow for a 4-week room temperature storage at any time during the entire 36-month approved shelf life.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2023 financial results on February 28, 2024, after the U.S. financial markets close.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, announced its first quarter 2024 financial results and provided a business update.